News

CataloniaBio & HealthTech has awarded IMIDomics with the Bioèxit Award


Cataloniabioht news Award acceptance speech by co-funder and CMO, Dr. Sara Marsal

Mar 23, 2022

Date Title
2022 Mar 23 CataloniaBio & HealthTech has awarded IMIDomics with the Bioèxit Award | Award acceptance speech by co-funder and CMO, Dr. Sara Marsal
2022 Feb 15 IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE
2021 Dec 7 IMIDomics™ Announces Scientific and Business Advisory Boards
2021 Oct 7 IMIDomics sponsors the online Symposium “Combination therapies in common diseases: clinical and translational challenges”, October 7th 2021
2021 Jul 27 IMIDomics™ Closes $16.5 Million Series A Financing to Advance its Precision Discovery Platform for Immune-Mediated Inflammatory Diseases
2021 Jul 20 IMIDomics co-organizes symposium "Combination therapies in common diseases: clinical and translational challenges"
2020 Oct 16 Drug candidate for severe COVID-19 identified by IMIDomics and VHIR Rheumatology Group selected for NIH clinical trial
2020 May 20 IMIDomics funds a study that identifies a new drug candidate to prevent severe COVID-19
2020 Feb 02 IMIDomics and Gossamer Bio Enter into a Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
2019 Dec 01 IMIDomics granted Horizon 2020 project on Systems approaches for the discovery of combinatorial therapies for complex disorders (H2020-SC1-BHC-2018-2020 Call)
2018 Oct IMIDomics listed as among the repositories with highest quality clinical data in the McKinsey 2017 Digital R&D report
2017 May 31 IMIDomics SL and Celgene Corporation Enter into Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
Showing 11 to 20 of 91 entries